Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activation.

@article{Abraham2007SynthesisOT,
  title={Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activation.},
  author={Sunny Abraham and Fang Guo and Lian-sheng Li and Christoph Rader and Cheng Liu and Carlos F. Barbas and Richard Allen Lerner and Subhash C. Sinha},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2007},
  volume={104 13},
  pages={5584-9}
}
An obstacle in the utilization of catalytic Abs for selective prodrug activation in cancer therapy has been systemic tumor targeting. Here we report the generation of catalytic Abs that effectively target tumor cells with undiminished prodrug activation capability. Ab conjugates were prepared by covalent conjugation of an integrin alpha(v)beta(3)-targeting… CONTINUE READING